Atrial Fibrillation and Percutaneous Coronary Intervention

Atrial Fibrillation and Percutaneous Coronary Intervention

A Case-based Guide to Oral Anticoagulation, Antiplatelet Therapy and Stenting

;

Springer International Publishing AG

07/2018

212

Mole

Inglês

9783319825717

15 a 20 dias

464

Descrição não disponível.
Atrial fibrillation on vitamin K-antagonists undergoing elective coronary artery stenting for stable effort angina.- Atrial fibrillation on NOAC (dabigatran) undergoing elective coronary artery stenting for stable effort angina.- Atrial fibrillation on vitamin K-antagonist undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome.- Atrial fibrillation on NOAC (rivaroxaban) undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome.- Atrial fibrillation on vitamin K-antagonist undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction.- Atrial fibrillation on NOAC (apixaban) undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction.- Atrial fibrillation early complicating acute coronary syndrome treated with coronary artery stenting.- New-onset atrial fibrillation in a stable patient with remote coronary artery stenting.- Urgent surgery early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel.- Urgent surgery early after coronary stenting in a patjent with atrial fibrillation on triple therapy of NOAC (a factor Xa-inhibitor), aspirin and clopidogrel.- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel.- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of NOAC (dabigatran), aspirin and clopidogrel.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Non vitamin K-antagonist oral anticoagulants;Oral anticoagulation;Percutaneous coronary intervention;Stent;Vitamin K-antagonists;pharmacotherapy